Genoa Ventures is a venture capital firm that specializes in investing in early-stage life sciences companies. The firm focuses on supporting innovative startups that are developing breakthrough technologies in the healthcare sector.

Jenny Rooke

Genoa Ventures

Genoa Ventures invests in early-stage companies innovating at the convergence of biology and technology. 

Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and don't neatly fit most VC’s patterns and boxes.

Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential.

We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.

Intabio

Zephyrus Biosciences

Zymergen

Caribou Biosciences

Great science can form the foundation for a world-changing company. But innovative and transformative ideas require significant vision, work, investment, and perseverance to move out of the lab and into the market.

In our new video series, 2022 Chemistry Nobel Laureate Carolyn Bertozzi Ph.D., joins Genoa Ventures Founder and Managing Director Jenny Rooke Ph.D., to discuss how to translate scientific developments and academic research into blockbuster businesses. They revisit the inception of their collaboration and how the intersection of interdisciplinary innovations led to Dr. Bertozzi’s founding of numerous start-up, including Genoa’s portfolio company InterVenn Biosciences.

Watch the full length video here: https://lnkd.in/eRdRn6bc

#nobellaureate #venturecapital #genoaportco #biotech #datascience

Genoa Venture Partner William (Bill) Hyun, PhD, participated in a panel at #AACR2024 this weekend, discussing the Road to Entrepreneurship and how early-stage companies can find investors. 

Bill has been a founder, investor, and advisor to over 50 companies. He coaches based on his success in combining sound science with sophisticated technologies and applying their synergy to pivotal points in transforming markets. 

Bill isn’t the only Genoa Ventures affiliate at AACR this week! Our #portco Aqtual, Inc. will also be sharing new findings. Stay tuned for more! 

Metric
Company Name	Genoa Ventures
Symbol
MSH ID	COM:GENOAVC
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	US
Stage
Employee Count	14
Website	genoavc.com
LinkedIn	genoaventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GENOAVC

Genoa Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue